Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients

Yi-Heng Li, Hung I. Yeh, Jiann Shing Jeng, Min Ji Charng

Research output: Contribution to journalReview article

Abstract

Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared.

Original languageEnglish
Pages (from-to)853-859
Number of pages7
JournalJournal of the Chinese Medical Association
Volume81
Issue number10
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Taiwan
Guidelines
Lipids
Cardiovascular Diseases
Dyslipidemias
Hyperlipoproteinemia Type II
Expert Testimony
Risk Reduction Behavior
Chronic Renal Insufficiency
Life Style
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{35ab4c713df94378abf6700a7a59ba05,
title = "Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients",
abstract = "Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared.",
author = "Yi-Heng Li and Yeh, {Hung I.} and Jeng, {Jiann Shing} and Charng, {Min Ji}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.jcma.2018.05.003",
language = "English",
volume = "81",
pages = "853--859",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "10",

}

Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients. / Li, Yi-Heng; Yeh, Hung I.; Jeng, Jiann Shing; Charng, Min Ji.

In: Journal of the Chinese Medical Association, Vol. 81, No. 10, 01.10.2018, p. 853-859.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients

AU - Li, Yi-Heng

AU - Yeh, Hung I.

AU - Jeng, Jiann Shing

AU - Charng, Min Ji

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared.

AB - Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared.

UR - http://www.scopus.com/inward/record.url?scp=85049337985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049337985&partnerID=8YFLogxK

U2 - 10.1016/j.jcma.2018.05.003

DO - 10.1016/j.jcma.2018.05.003

M3 - Review article

VL - 81

SP - 853

EP - 859

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 10

ER -